Playing a key role in developing life-saving cancer immunotherapies

Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity

Findings point to new therapeutic strategy to maximize dendritic cell-induced T-cell activation with potential to benefit patients as a single agent and in combination with immune checkpoint inhibitors.

View Research Article

Researchers discover new pathways to activate dendritic cells, produce strong anti-tumor immunity

Oncolytic virus expressing CD40 ligand and IFNβ reduces tumor size, activates immune cells in phase 1 trial

View Press Release

Management Team and Board of Directors

We have a track record of success in the biotechnology, pharmaceutical, and finance sectors.


Gregory Brown, MD, MBA
Chief Executive Officer
Director
View Bio
Gregory Brown, MD, MBA
Chief Executive Officer
Director

Extensive career bridging scientific and financial expertise in life sciences. Founder and Vice Chairman of HealthCare Royalty Partners (“HCR”). MBA from Harvard Business School, an MD from SUNY Upstate College of Medicine, and a BA from Yale University.

Mark Cantwell, PhD
Chief Scientific Officer
Director
View Bio
Mark Cantwell, PhD
Chief Scientific Officer
Director

Extensive research and industry experience in cancer immunotherapy drug discovery and development. Inventor on multiple patented technologies, including Memgen’s viral cancer immunotherapies. PhD in Biomedical Sciences from the University of California San Diego.

Robert Coates, PhD
Chief Operating Officer
Chairman of the Board
View Bio
Robert Coates, PhD
Chief Operating Officer
Chairman of the Board

Dr. Coates is the founder and lead investor in Memgen. MBA and PhD in Finance, Accounting, and Economics from the University of Chicago Graduate School of Business.

Patricia Bitar
Director
View Bio
Patricia Bitar
Director

Chief Financial Officer of Tracon Pharmaceuticals 2014-18 where she oversaw Tracon’s $41 million IPO and subsequent financings totaling over $100 million. Previous experience includes senior accounting positions at NuVasive and Orexigen Therapeutics and various CFO/accounting consulting roles.

Casey Logan
Director
View Bio
Casey Logan
Director

Senior Vice President, Corporate & Business Development at Travere Therapeutics. Prior to Travere, Chief Business Officer at Tracon Pharmaceuticals. Before joining Tracon held senior corporate development roles at Bird Rock Bio and Anadys Pharmaceuticals (acquired by Roche).

Christopher Pagano
Director
View Bio
Christopher Pagano
Director

Former Chief Investment Officer, Chief Financial Officer, and Chief Risk Officer with Assurant, Inc. a NYSE-traded insurance company, over twenty-three years. MBA from the University of Chicago Graduate School of Business and a BS in Economics from the University of Pennsylvania Wharton School.

John Poulos
Director
View Bio
John Poulos
Director

Deeply experienced pharmaceutical senior executive. Former Global Head of Corporate Development at Abbott and AbbVie, responsible for multiple major acquisitions, including Pharmacyclics ($21 billion) and Knoll/BASF ($6.9 billion).

Steven Whitley
Director
View Bio
Steven Whitley
Director

Founding member of Wiltshire, Whitley, Richardson & English, PA, a full-service accounting firm offering a comprehensive range of business and personal accounting services. He is a member of the American Institute of Certified Public Accountants (AICPA) and the Florida Institute of Certified Public Accountants (FICPA).

Scientific Advisory Board

Our board provides the expertise and guidance necessary to develop our cancer immunotherapies.


View Our Scientific Advisory Board

Our Science


Memgen’s
CD40 Ligand

A patented, safe and effective biological.

Memgen is applying its expertise in immune-regulatory systems to develop a range of immunotherapies, including viral immunotherapies, cell-based immunotherapies (TILs), and infectious disease vaccine adjuvants. Our immunotherapies are designed with multimodal mechanisms of action capable of working as single agents or in combination with checkpoint inhibitors and other therapies to maximize therapeutic benefit with a desirable safety profile.

Memgen’s immunotherapies leverage the power of our proprietary clinically evaluated CD40 ligand in combination with other co-stimulatory genes. MEM-288, our lead product candidate, combines our CD40 ligand with interferon beta (IFNβ). This combination has been engineered by Memgen and Moffitt Cancer Center to provide the optimum capability to generate a robust, whole-body, tumor-targeted T cell immune response.

The combination of a highly active viral immunotherapy with two potent transgenes turns Memgen's MEM-288 into a “triple threat” attacking cancers with three discrete mechanisms.

Partnering


Memgen is actively seeking strategic partnership and business opportunities with pharmaceutical and biotechnology companies for expanded research and clinical development.

2023 BIO International Convention

June 5-8, 2023 | Boston, MA

Memgen will be attending the 2023 BIO International Convention in Boston, MA (June 5-8, 2023). We look forward to connecting with you.

Contact Us   Conference Info

2023 ASCO Annual Meeting

June 2-6, 2023 | Chicago, IL & Online

Memgen will be attending the 2023 ASCO Annual Meeting in Chicago, IL & Online (June 2-6, 2023). We look forward to connecting with you.

Contact Us   Conference Info

Contact Us


Memgen's Headquarters
12 Greenway Plaza
Suite 1100
Houston, TX 77046

For company inquiries and partnering please contact:
Dr. Greg Brown, Memgen’s CEO
gbrown@memgenbio.com